Pneumonia, Viral Clinical Trial
Official title:
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2, name of the Coronavirus Group of international Committee on taxonomy of viruses, is an emerging virus from the family of coronaviridae, responsible for the COVID-19 pandemic. This infection can progress to viral pneumonia, and in 3% of cases up to acute respiratory distress syndrome (ARDS) which conditions the prognosis of the disease. Due to its unusual clinical presentation with a risk of sudden deterioration on the 8th day as a result of possible hyperinflammatory response, the respiratory impairment of COVID is unique and many questions remain unanswered concerning its evolution once the acute phase has passed. Knowledge of the evolution of pulmonary involvement, particularly in patients requiring hospitalization, can help reduce the morbidity linked to the persistent abnormalities identified by establishing early therapeutic management. It can also provide a better understanding of the mechanisms of pulmonary involvement in the acute phase. Current data regarding the acute phase of COVID-19 suggest that persistent abnormalities remain distant from this infection at all levels of the respiratory system: gas exchange, perfusion, ventilatory mechanics, and interstitial lung disease. The main objective is to characterize persistent gas exchange anomalies 4 months after documented COVID-19 pneumonia, resulting in oxygen desaturation and requiring hospitalization.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04517123 -
Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
|
N/A | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
| Completed |
NCT04724538 -
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04414293 -
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
|
N/A | |
| Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
| Recruiting |
NCT04528888 -
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
|
Phase 3 | |
| Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
| Terminated |
NCT04619693 -
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
|
||
| Recruiting |
NCT05077917 -
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
|
Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
| Active, not recruiting |
NCT04381364 -
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
|
Phase 2 | |
| Completed |
NCT04479540 -
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
|
N/A | |
| Recruiting |
NCT04474340 -
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
|
Phase 1 | |
| Completed |
NCT04424836 -
HFNC Treatment in COVID-19 Pneumonia
|
||
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04387799 -
Determinants of COVID-19 Pneumonia (MC-19)
|
||
| Completed |
NCT04382547 -
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04399681 -
The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19
|
N/A |